IL-1 beta modulation of spontaneous autoimmune diabetes and thyroiditis in the BB rat

Wilson, C.A.; Jacobs, C.; Baker, P.; Baskin, D.G.; Dower, S.; Lernmark, A.; Toivola, B.; Vertrees, S.; Wilson, D.

Journal of Immunology 144(10): 3784-3788

1990


ISSN/ISBN: 0022-1767
PMID: 2332631
Document Number: 366277
Long term effects of in vivo treatment with human rIL-1 beta on diabetogenesis and thyroid disease were determined in the Biobreeding rat. Administration of high dose (10 micrograms/kg) IL-1 beta accelerated the onset of insulin-dependent diabetes mellitus compared to saline-injected controls. High dose treatment resulted in goiter development, pronounced LT, reduced serum T4 levels, and overall growth reduction. In contrast, low dose IL-1 beta (0.5 microgram/kg) administration significantly reduced the frequency of insulin-dependent diabetes mellitus (48%) compared to placebo (86%) and high dose IL-1 beta (93%) treatment groups. Rats protected by low dose IL-1 beta had unaffected growth rates and minimal to no pancreatic and thyroid pathology. Our results demonstrate that exogenous administration of IL-1 beta modulates Biobreeding rat idiopathic autoimmune diabetes and thyroid disease in a dose-dependent manner.

Document emailed within 1 workday
Secure & encrypted payments